What Is Hormone Replacement Therapy for Trans Youth? A Sourced Guide

TransHealthHub
Aug 7
4 min read

Updated: 7 days ago

TransHealthHub | Reviewed as of August 2026

KEY TAKEAWAYS

Hormone replacement therapy for trans youth, often called gender-affirming hormone therapy, means estrogen (for a feminizing effect) or testosterone (for a masculinizing effect) to bring the body in line with a young person's gender identity.
It is not used before puberty. Clinical guidelines generally reserve it for older adolescents, most often around age 16, after multidisciplinary assessment and informed consent.
Some effects are reversible if the medication stops; others, such as breast growth or voice deepening, are permanent. This is why fertility and permanence are discussed carefully beforehand.
U.S. medical bodies view it as an appropriate option for carefully assessed adolescents, and studies link it to improved mental health. Several evidence reviews rate the long-term certainty of that evidence as low, and this is genuinely contested.
Availability depends heavily on your state.

THE SHORT ANSWER

Hormone replacement therapy, in the context of trans youth, means giving estrogen or testosterone so that an adolescent's body develops characteristics matching their gender identity. At TransHealthHub, the framing we find most useful for parents is that this is a later, carefully gated step, not a starting point. It is distinct from puberty blockers, which only pause puberty, and it is not something offered to young children. You may also see this treatment called gender-affirming hormone therapy or GAHT; the terms refer to the same thing.

HOW HORMONE THERAPY WORKS

The goal, as the Endocrine Society describes it, is to introduce the hormone of the affirmed gender at a gradually increasing dose that mimics a typical puberty. For a transgender girl, that means estrogen, sometimes with a medication to reduce testosterone's effects. For a transgender boy, it means testosterone. Doses are adjusted over two to three years to reach levels typical for the affirmed gender, and clinicians monitor bloodwork and effects every few months.

Timing follows the evidence and the guidelines. Hormone therapy is not recommended for prepubertal children. The Endocrine Society guideline suggests that clinicians may add gender-affirming hormones after a team confirms that gender dysphoria has persisted and that the adolescent can give informed consent, noting that most reach this capacity around age 16 and that experience treating before roughly 13.5 to 14 is minimal. Where blockers fit ahead of this step is covered in our guide to puberty blockers.

WHAT CHANGES AND WHAT IS PERMANENT

Being clear about reversibility matters more here than almost anywhere else, because some effects do not undo.

Testosterone (masculinizing)	Estrogen (feminizing)
Deeper voice (permanent)	Breast growth (permanent)
Facial and body hair (partly lasting)	Softer skin, fat redistribution (reversible)
Stopped periods (reversible)	Reduced muscle mass (reversible)
Clitoral growth (permanent)	Slower body-hair growth (reversible)
Acne, possible scalp hair loss	No change to voice pitch

Because several changes are lasting, guidelines call for counseling on fertility preservation before treatment, and for ongoing monitoring of bone health, metabolic markers, and blood counts.

WHAT THE EVIDENCE SAYS ABOUT THE BENEFITS

The clinical case for hormone therapy rests largely on mental health. A widely cited prospective study of transgender and nonbinary youth found that receiving puberty blockers or hormones was associated with 60% lower odds of depression and 73% lower odds of suicidality over 12 months. A 2025 review similarly reported improvements in depression, anxiety, and body-related distress among youth receiving this care.

We want to be precise rather than sweeping. That same prospective study found no significant change in anxiety, and much of this literature is observational, often without a comparison group of youth who wanted care but did not receive it. The near-term mental-health signal is consistent across studies; the long-term and higher-certainty evidence is thinner. Both statements are true at once.

WHERE CREDIBLE CAUTION COMES IN

Reputable authorities have looked at the same evidence and urged more caution about certainty. England's Cass Review judged the evidence base for hormonal treatment in minors to be weak, and NHS England moved to restrict routine prescribing, recommending against gender-affirming hormones for under-16s and, in a 2026 consultation, weighing whether to stop routine prescription for under-18s altogether. A 2025 U.S. Department of Health and Human Services report reached a similar conclusion on evidence quality.

Two points keep this in proportion. These reviews concern the certainty of long-term evidence, graded low under formal tools, rather than proof of harm. And they are contested: the American Academy of Pediatrics, the Endocrine Society, and WPATH have disputed both the conclusions and, for the Cass Review, its methods. A parent deserves to know that qualified experts genuinely disagree here.

AVAILABILITY IN THE US

Access is a matter of geography. Hormone therapy is among the treatments restricted for minors in roughly two dozen states following the Supreme Court's 2025 decision in United States v. Skrmetti, which we explain in our overview of gender-affirming care. In states without bans, it remains available through qualified clinicians, typically within a multidisciplinary team.

FREQUENTLY ASKED QUESTIONS

Is hormone replacement therapy given to young children? No. It is not used before puberty, and guidelines generally reserve it for older adolescents.

Are the effects reversible? Some are, such as fat redistribution or stopped periods. Others, including breast growth, voice deepening, and clitoral growth, are permanent. This is discussed in detail before starting.

Does it affect fertility? It can. Guidelines call for fertility counseling before treatment so that options are understood in advance.